Direct evidence of cellular transformation by prion-like p53 amyloid infection
- PMID: 34085695
- DOI: 10.1242/jcs.258316
Direct evidence of cellular transformation by prion-like p53 amyloid infection
Abstract
Tumor suppressor p53 mutations are associated with more than 50% of cancers. Aggregation and amyloid formation of p53 is also implicated in cancer pathogenesis, but direct evidence for aggregated p53 amyloids acting as an oncogene is lacking. Here, we conclusively demonstrate that wild-type p53 amyloid formation imparts oncogenic properties to non-cancerous cells. p53 amyloid aggregates were transferred through cell generations, contributing to enhanced survival, apoptotic resistance with increased proliferation and migration. The tumorigenic potential of p53 amyloid-transformed cells was further confirmed in mouse xenografts, wherein the tumors showed p53 amyloids. p53 disaggregation rescued the cellular transformation and inhibited tumor development in mice. We propose that wild-type p53 amyloid formation contributes to tumorigenesis and can be a potential target for therapeutic intervention. This article has an associated First Person interview with the first author of the paper.
Keywords: Amyloid; Cancer initiation; Prion; Tumor suppressor; Tumorigenesis; p53.
© 2021. Published by The Company of Biologists Ltd.
Conflict of interest statement
Competing interests The authors declare no competing or financial interests.
Similar articles
-
Oncogenic gain of function due to p53 amyloids occurs through aberrant alteration of cell cycle and proliferation.J Cell Sci. 2022 Aug 1;135(15):jcs259500. doi: 10.1242/jcs.259500. Epub 2022 Aug 1. J Cell Sci. 2022. PMID: 35796018
-
Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.J Biol Chem. 2012 Aug 10;287(33):28152-62. doi: 10.1074/jbc.M112.340638. Epub 2012 Jun 19. J Biol Chem. 2012. PMID: 22715097 Free PMC article.
-
Phase Separation and Prion-Like Aggregation of p53 Family Tumor Suppressors: From Protein Evolution to Cancer Treatment.J Neurochem. 2025 Apr;169(4):e70055. doi: 10.1111/jnc.70055. J Neurochem. 2025. PMID: 40178008 Review.
-
Prion-like aggregation of mutant p53 in cancer.Trends Biochem Sci. 2014 Jun;39(6):260-7. doi: 10.1016/j.tibs.2014.04.001. Epub 2014 Apr 26. Trends Biochem Sci. 2014. PMID: 24775734 Review.
-
p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis.Cell Death Differ. 2017 Oct;24(10):1784-1798. doi: 10.1038/cdd.2017.105. Epub 2017 Jun 23. Cell Death Differ. 2017. PMID: 28644435 Free PMC article.
Cited by
-
p53 amyloid aggregation in cancer: function, mechanism, and therapy.Exp Hematol Oncol. 2022 Sep 28;11(1):66. doi: 10.1186/s40164-022-00317-7. Exp Hematol Oncol. 2022. PMID: 36171607 Free PMC article. Review.
-
Oncogenic p53 triggers amyloid aggregation of p63 and p73 liquid droplets.Commun Chem. 2024 Sep 16;7(1):207. doi: 10.1038/s42004-024-01289-x. Commun Chem. 2024. PMID: 39284933 Free PMC article.
-
Protein of a thousand faces: The tumor-suppressive and oncogenic responses of p53.Front Mol Biosci. 2022 Aug 25;9:944955. doi: 10.3389/fmolb.2022.944955. eCollection 2022. Front Mol Biosci. 2022. PMID: 36090037 Free PMC article. Review.
-
Realization of Amyloid-like Aggregation as a Common Cause for Pathogenesis in Diseases.Life (Basel). 2023 Jul 7;13(7):1523. doi: 10.3390/life13071523. Life (Basel). 2023. PMID: 37511898 Free PMC article. Review.
-
Transition of amyloid/mutant p53 from tumor suppressor to an oncogene and therapeutic approaches to ameliorate metastasis and cancer stemness.Cancer Cell Int. 2022 Dec 26;22(1):416. doi: 10.1186/s12935-022-02831-4. Cancer Cell Int. 2022. PMID: 36567312 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous